EpiVax Acquired by SV Health Investors to Expand Immunogenicity CRO Capabilities

• EpiVax has been acquired by SV Health Investors, a healthcare and life sciences-focused private investment firm.

• The acquisition is intended to accelerate expansion of EpiVax’s immunogenicity risk assessment capabilities and CRO services.

EpiVax announced it has been acquired by SV Health Investors (SVHI), a private investment firm focused on healthcare and life sciences. The transaction marks a new phase for the bioanalytical CRO, which specializes in immunogenicity risk assessment for pharmaceutical and biotechnology companies. 

Founded in 1998 and headquartered in Providence, Rhode Island, EpiVax has developed computational immunology tools and laboratory services used to evaluate immune responses and safety risks during drug development. The company supports programs from early discovery through clinical development using proprietary software and in-vitro testing capabilities. 

According to the announcement, the partnership with SV Health Investors is expected to accelerate development of new computational tools, expand cell-based assay applications, and broaden consulting services. The investment represents a platform opportunity for SV Health Investors in outsourced pharmaceutical services. 

The company also noted that its founders will continue supporting the organization in advisory roles following the transaction, while the leadership team focuses on expanding scientific capabilities and global partnerships. The move follows recent additions to EpiVax’s scientific leadership and continued investment in immunogenicity research technologies. 

“This partnership marks an important next chapter for EpiVax and reflects SV Health Investors’ confidence in our leadership team, differentiated capabilities, and scientific expertise.” 

Annie De Groot, MD, Founder of EpiVax